A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Phase of Trial: Phase II/III
Latest Information Update: 07 Feb 2019
At a glance
- Drugs Baricitinib (Primary)
- Indications Alopecia areata
- Focus Therapeutic Use
- Acronyms BRAVE-AA1
- Sponsors Eli Lilly
- 18 Dec 2018 Planned End Date changed from 25 Mar 2022 to 5 Aug 2022.
- 19 Nov 2018 Planned End Date changed from 5 Aug 2022 to 25 Mar 2022.
- 26 Sep 2018 Status changed from not yet recruiting to recruiting.